Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pre-emption Limits Survive Congress, But Will Face Supreme Court

This article was originally published in The Tan Sheet

Executive Summary

The FDA reauthorization law signed by President Bush Sept. 27 includes provisions intended to sustain limits on federal pre-emption, but the concept is challenged in several ongoing cases that could reach the Supreme Court in coming sessions

You may also be interested in...



FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research

FDA Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, the agency says

FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research

FDA Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, the agency says

FDA Stymied By Reauthorization Terms That May Slow Ingredient Development

FDA is stumped on interpreting and enforcing a provision in the FDA Amendments Act of 2007 that could have a chilling effect on development of new functional food and dietary supplement ingredients, an FDA official and an industry leader say

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel